Share-based Payment Arrangement, Expense of bioAffinity Technologies, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
bioAffinity Technologies, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • bioAffinity Technologies, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $67,132, a 64% decline year-over-year.
  • bioAffinity Technologies, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $839,442, a 23% decline year-over-year.
  • bioAffinity Technologies, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $989,681, a 32% increase from 2023.
  • bioAffinity Technologies, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $748,823, a 201% increase from 2022.
  • bioAffinity Technologies, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $248,592, a 99% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

bioAffinity Technologies, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $839,442 $67,132 -$118,555 -64% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $957,997 $211,607 -$75,687 -26% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,033,684 $326,616 +$44,003 +16% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $989,681 $234,087 -$101,624 -30% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $1,091,305 $185,687 +$100,442 +118% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $990,863 $287,294 +$117,040 +69% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $873,823 $282,613 +$125,000 +79% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $748,823 $335,711 +$298,864 +811% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $449,959 $85,245 +$6,232 +7.9% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $443,727 $170,254 +$143,569 +538% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $300,158 $157,613 +$51,566 +49% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $248,592 $36,847 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $79,013 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $26,685 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $106,047 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1

bioAffinity Technologies, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $989,681 +$240,858 +32% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $748,823 +$500,231 +201% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $248,592 -$42,763,408 -99% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $43,012,000 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.